KGK and Herbicure sign North America/India deal
with the Indian firm Herbicure and made new agreements with
suppliers in China.
After a visit to Kolkata (formerly Calcutta) by representatives from KGK, the company was named the North American representative of Herbicure's products, while Herbicure will be responsible for KGK's products in India.
Herbicure's product line includes Panekure, a product claimed to reduce pain, and Asmakure aimed at the relief of asthma symptoms.
Najla Guthrie, the CEO of KGK, said after a visit round Herbicure's plant, that she was impressed by it and the firm's clinical trial facilities.
"We are confident they can deliver high-quality, clinically tested nutraceutical products, and facilitate our human clinical trials," she said, adding companies will now be able to carry out larger tests without suffering the high costs of North America.
Meanwhile, the Canadian company recently completed a visit to China aimed at ensuring its ingredients suppliers' facilities meet the required standards.
The sites looked at included Chengdu Superman Pharmaceutical, where an agreement was finalized to produce and supply KGK with ingredients for various forthcoming products.
This was followed by a visit to Chengdu Wagott Natural Products, a supplier of raw materials for its cholesterol-lowering product Sytrinol that is derived from citrus and composed of polymethoxylated flavones and tocotrienols.
Fenchem Enterprises in Nanjing was then given the once over, before arriving at the Food Engineering Research Center of State Education Ministry in southern China.
KGK had nothing but praise for the final two facilities and the meeting with the Food Engineering Research Center concluded with KGK agreeing to assist Shenzhen Leading Biotech to bring their products to the North American market, while Shenzhen will market KGK's products. KGK also discussed using their research facility as an additional site for conducting human clinical trials.
